Draupnir Bio

Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is enabling the development of protein degraders that target extracellular disease proteins, with potential to target 40% of the human proteome and offering broad disease applicability across multiple areas. Through this differentiated platform technology, it’s building a broad pipeline of oral small molecule degraders of extracellular pathogenic proteins.

Info & Contact


Draupnir Bio ApS
CVR no. 38 54 68 80
Solsikkevej 8
8240 Risskov

In portfolio

27. Dec 2018

HTGF Manager

Dr. Natalya Baltrukovich, Investment Manager